Please confirm that an ethics committee approval has been applied for or granted: Yes: I’m uploading the Ethics Committee Approval as a PDF file with this abstract submission

Background and Aims Dexmedetomidine is used as a perineural adjuvant associated with local anesthetic, which exerts protective effects in addition to its sedative and analgesic properties. Dexmedetomidine provides prolongation of the peripheral nerve block as well as postoperative analgesia

Methods We conducted a prospective comparative study including a series of 194 Sick since August 2014, the patients were randomly divided into two groups undergoing knee surgery such as ligamentoplasty. Group M: a series of 97 patients who received dexmedetomidine a reason (0.5 μg/kg) or 50 μg in 15 ml of 0.5% ropivacaine. Group C: a series of 97 patients who received clonidine at a rate of 1μg/kg with ropivacaine at 0.5% and implemented at the end of the procedure of a nerve analgesia catheter in the saphenous vein maintains with ropivacaine 0.2% in 8ml/h

Results The two groups were comparable in terms of age, sex, BMI and ASA. most of the patients were done with 4 blocks therefore associated with the lateral thigh, and the surgery done under arthroscopy; Patients in both groups received on average the same volumes of local anesthetic. The average duration of the intervention was one hour.

Conclusions Dexmedetomidine is a promising agent for the improvement and prolongation of peripheral nerve blocks by combining it with a long-lasting local anesthetic. The aim of which is to combat postoperative pain for very painful surgeries. The methods of use of adjuvants are based as much on their pharmacodynamic properties as on the overall strategy for postoperative pain management.